LDS/Medical Tests/Colon Cancer Multi-Gene Panel, NGS (ColoNext®, COLONSEQ, COLONSEQPlus)

Colon Cancer Multi-Gene Panel, NGS (ColoNext®, COLONSEQ, COLONSEQPlus)

Colon cancer is one of the most common malignant tumors affecting both males and females. Selection of therapy is important since the therapeutic efficacy has been shown to be dependent on the gene mutations present in an individual’s cancer. Therefore, testing for common gene mutations that impact therapy is recommended for all colon cancer patients. Testing for individual gene mutations is time-consuming and cumbersome. Incorporation of the common genes within a multi-gene panel testing is useful in the timely evaluation and appropriate therapy selection in colon cancer.

Although the genes included in individual panels depends on the laboratory, the commonly incorporated genes include APC, MUTYH, SMAD4, BMPR1A, STK11, PTEN, MLH1, MSH2, MSH6, PMS2, EPCAM, TP53, AXIN2, GREM1, MSH3, NTHL1, POLE, POLD1 or GALNT12, and others. Generally, somatic and germline mutations in these genes are associated with the development of colon cancer. The panel testing utilizes targeted next-generation sequencing (NGS) to evaluate the most common variants within genes. An advantage of this testing is that it can detect and identify more genetic mutations as compared to phenotype-based sequencing.

In addition to its utility in the diagnosis and management of colon cancer, the panel testing is also useful to guide treatment with anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibodies such as cetuximab and panitumumab. Mutations in genes BRAF, KRAS, NRAS, and PIK3CA generally confer resistance to these drugs. Thus, the panel can also be considered predictive testing in determining the efficacy of anti-EGFR therapy. Finally, the evaluation of microsatellite instability (MSI) is recommended in all colon cancers.

  • Aids in diagnosing colorectal cancer
  • To guide treatment with anti-EGFR monoclonal antibodies (eg, cetuximab and panitumumab)
  • Aids in screening neonates and family members with a history of colon cancer
  • Selection of therapy and disease management.
  • Predicts the efficacy of anti-EGFR therapy

A positive result indicates the presence of mutations in one or more targeted genes thus identifying the gene involved and indicating the risk of future colon cancer.

  • High risk genes - APC, BMPR1A, EPCAM, MLH1, MSH2, MSH6, MUTYH, PMS2, SMAD4, STK11
  • Moderate risk genes - CHEK2, PTEN, TP53
  • Low risk genes- CDH, EXO1, GALNT12, MUTYH, POLD1, POLE(Patients with positive results on BRAF, KRAS, NRAS, and PIK3CA genes are resistant to anti-EGFR therapy)

A negative result indicates the absence of mutations in the targeted genes.

Negative for mutations. (No mutations on the targeted genes were detected)

Targeted-next generation sequencing (NGS).

Whole blood (EDTA), Formalin-fixed paraffin-embedded (FFPE) colorectal carcinoma (CRC) tissue.

Stability Whole blood

  • Ambient: 3-5 days
  • Refrigerated: 7-14 days
  • Frozen: Unstable

FFPE: stable at room temperature for longer.

Carcinoembryonic antigen (CEA), Colon biopsy.
2-3 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Frontiers in oncology. 2015 Sep 29;5:208. [PMID: 26484312]
  • Crit Rev Oncol Hematol. 2010;74:106–33. [PMID: 20138539]
  • J Transl Med. 2017 Dec 8;15(1):246. [PMID: 29221448]
  • Gastroenterol Clin North Am. 2008 Mar;37(1):1-24. [PMID: 18313537]
  • Minerva Gastroenterol Dietol. 2007 Dec;53(4):351-73. [PMID: 18043553]
  • El Bairi K, Lengyel C, Marra A, Afqir S. Colorectal Cancer Genetics: An Overview of the Actionable Building Blocks.
  • Illuminating Colorectal Cancer Genomics by Next-Generation Sequencing. 2020:29-71.
  • El Bairi K, Afqir S. Next-Generation Sequencing for Colorectal Cancer Management. InIlluminating Colorectal Cancer Genomics by Next-Generation Sequencing 2020 (pg. 91-110). Springer, Cham.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login